WO2003074004A2 - Procede de production d'antigenes - Google Patents

Procede de production d'antigenes Download PDF

Info

Publication number
WO2003074004A2
WO2003074004A2 PCT/US2003/006661 US0306661W WO03074004A2 WO 2003074004 A2 WO2003074004 A2 WO 2003074004A2 US 0306661 W US0306661 W US 0306661W WO 03074004 A2 WO03074004 A2 WO 03074004A2
Authority
WO
WIPO (PCT)
Prior art keywords
cross
compound
transglutaminase
recombinant
antigen
Prior art date
Application number
PCT/US2003/006661
Other languages
English (en)
Other versions
WO2003074004A3 (fr
Inventor
Szu-Yi Chou
Original Assignee
Szu-Yi Chou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/231,063 external-priority patent/US20030224476A1/en
Priority claimed from US10/231,213 external-priority patent/US20040001848A1/en
Priority claimed from US10/231,470 external-priority patent/US7101695B2/en
Priority claimed from US10/231,298 external-priority patent/US20030219853A1/en
Priority claimed from US10/231,114 external-priority patent/US7485438B2/en
Application filed by Szu-Yi Chou filed Critical Szu-Yi Chou
Priority to AU2003213718A priority Critical patent/AU2003213718A1/en
Publication of WO2003074004A2 publication Critical patent/WO2003074004A2/fr
Publication of WO2003074004A3 publication Critical patent/WO2003074004A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/104—Aminoacyltransferases (2.3.2)
    • C12N9/1044—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Abstract

Des modes de réalisation de l'invention concernent en général des procédés et des compositions permettant de produire des antigènes polyvalents, des antigènes spécifiques de maladies, des composés réactifs à la transglutaminase, et des transglutaminases recombinées. L'invention concerne également un procédé de production d'un composé réticulé par un agent biologique. L'invention concerne également un procédé de production d'un antigène réticulé et un procédé d'utilisation de produits réticulés utilisés en tant qu'antigènes afin d'immuniser des animaux et d'induire de fortes réponses immunitaires. L'invention concerne également un procédé de production d'un antigène spécifique de la maladie d'Alzheimer. L'invention concerne également un procédé de production d'un antigène polyvalent pour au moins deux maladies. Ces compositions et ces antigènes sont ainsi préparés et administrés afin d'immuniser des animaux et d'induire de fortes réponses immunitaires. L'invention concerne en outre des transglutaminases recombinées purifiées réactives à une variété étendue de composés et qui présentent une grande activité de substrat. L'invention concerne enfin un procédé permettant de lier un ou plusieurs résidus d'amino-acides à un composé à faire réagir avec de la transglutaminase, y compris pour des composés non réactifs à la transglutaminase.
PCT/US2003/006661 2002-03-01 2003-03-03 Procede de production d'antigenes WO2003074004A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003213718A AU2003213718A1 (en) 2002-03-01 2003-03-03 Method of producing antigens

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US36116602P 2002-03-01 2002-03-01
US60/361,166 2002-03-01
US36344502P 2002-03-08 2002-03-08
US60/363,445 2002-03-08
US10/231,063 2002-08-28
US10/231,298 2002-08-28
US10/231,063 US20030224476A1 (en) 2002-03-01 2002-08-28 Method of producing transglutaminase reactive compound
US10/231,114 2002-08-28
US10/231,213 US20040001848A1 (en) 2002-03-01 2002-08-28 Method of producing disease-specific antigens
US10/231,470 US7101695B2 (en) 2002-03-01 2002-08-28 Method of producing transglutaminase having broad substrate activity
US10/231,298 US20030219853A1 (en) 2002-03-01 2002-08-28 Method of cross-linking a compound
US10/231,114 US7485438B2 (en) 2002-03-01 2002-08-28 Method of producing polyvalent antigens
US10/231,470 2002-08-28
US10/231,213 2002-08-28

Publications (2)

Publication Number Publication Date
WO2003074004A2 true WO2003074004A2 (fr) 2003-09-12
WO2003074004A3 WO2003074004A3 (fr) 2006-08-10

Family

ID=27792403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/006661 WO2003074004A2 (fr) 2002-03-01 2003-03-03 Procede de production d'antigenes

Country Status (2)

Country Link
AU (1) AU2003213718A1 (fr)
WO (1) WO2003074004A2 (fr)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072777A2 (fr) * 2004-01-28 2005-08-11 Curix Aps Methodes de prevention et de traitement de la maladie d'alzheimer et d'autres maladies associees aux amyloides
WO2007005358A2 (fr) * 2005-06-30 2007-01-11 Merck & Co., Inc. Procede de preparation d'un oligomere de peptides beta-amyloides reticule de maniere covalente
WO2008020075A1 (fr) * 2006-08-18 2008-02-21 Novo Nordisk Health Care Ag Variants de transglutaminase dotés d'une spécificité améliorée
WO2008102007A1 (fr) * 2007-02-22 2008-08-28 Novo Nordisk Health Care Ag Variants de transglutaminase à spécificité améliorée
WO2009153751A2 (fr) * 2008-06-18 2009-12-23 Lifebond Ltd Procédé de réticulation enzymatique d'une protéine
US9044456B2 (en) 2008-06-18 2015-06-02 Lifebond Ltd. Cross-linked compositions
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9636433B2 (en) 2006-12-15 2017-05-02 Lifebond Ltd Gelatin-transglutaminase hemostatic dressings and sealants
US9822171B2 (en) 2010-04-15 2017-11-21 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US10202585B2 (en) 2009-12-22 2019-02-12 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US10464976B2 (en) 2003-01-31 2019-11-05 AbbVie Deutschland GmbH & Co. KG Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
US10538581B2 (en) 2005-11-30 2020-01-21 Abbvie Inc. Anti-Aβ globulomer 4D10 antibodies

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008104386A2 (fr) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Méthode de traitement d'amyloïdoses
ES2567174T3 (es) 2010-08-05 2016-04-20 Lifebond Ltd Composición seca en apósitos y adhesivos para heridas

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544638A (en) * 1984-05-18 1985-10-01 The Regents Of The University Of California Synthesis of cross-links in the helical domain of collagen using pyridoxal 5-phosphate and copper or iron
US6010871A (en) * 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544638A (en) * 1984-05-18 1985-10-01 The Regents Of The University Of California Synthesis of cross-links in the helical domain of collagen using pyridoxal 5-phosphate and copper or iron
US6010871A (en) * 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DE JONG G.A.H. ET AL: 'Purification and substrate specificity of transglutaminase from blood and Streptoverticillium mobaraense' JOUR. AGRIC FOOD CHEM. vol. 49, 2001, pages 3389 - 3393, XP003001875 *
KAHLEM P. ET AL.: 'Peptides containing glutamine repeats as substrates for transglutaminase catalyzed cross-linking: Relevance to diseases of the nervous system' PROC. NATL. ACAD. SCI. USA vol. 93, 1996, pages 14580 - 14585, XP000918974 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10464976B2 (en) 2003-01-31 2019-11-05 AbbVie Deutschland GmbH & Co. KG Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof
WO2005072777A2 (fr) * 2004-01-28 2005-08-11 Curix Aps Methodes de prevention et de traitement de la maladie d'alzheimer et d'autres maladies associees aux amyloides
WO2005072777A3 (fr) * 2004-01-28 2006-06-15 Curix Aps Methodes de prevention et de traitement de la maladie d'alzheimer et d'autres maladies associees aux amyloides
WO2007005358A2 (fr) * 2005-06-30 2007-01-11 Merck & Co., Inc. Procede de preparation d'un oligomere de peptides beta-amyloides reticule de maniere covalente
WO2007005358A3 (fr) * 2005-06-30 2007-04-05 Merck & Co Inc Procede de preparation d'un oligomere de peptides beta-amyloides reticule de maniere covalente
US10323084B2 (en) 2005-11-30 2019-06-18 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US10208109B2 (en) 2005-11-30 2019-02-19 Abbvie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
US10538581B2 (en) 2005-11-30 2020-01-21 Abbvie Inc. Anti-Aβ globulomer 4D10 antibodies
WO2008020075A1 (fr) * 2006-08-18 2008-02-21 Novo Nordisk Health Care Ag Variants de transglutaminase dotés d'une spécificité améliorée
US9951125B2 (en) 2006-11-30 2018-04-24 Abbvie Inc. Aβ conformer selective anti-Aβ globulomer monoclonal antibodies
US9655988B2 (en) 2006-12-15 2017-05-23 Lifebond Ltd Gelatin-transglutaminase hemostatic dressings and sealants
US9636433B2 (en) 2006-12-15 2017-05-02 Lifebond Ltd Gelatin-transglutaminase hemostatic dressings and sealants
WO2008102008A1 (fr) * 2007-02-22 2008-08-28 Novo Nordisk Health Care Ag Variants de transglutaminase à spécificité améliorée
WO2008102007A1 (fr) * 2007-02-22 2008-08-28 Novo Nordisk Health Care Ag Variants de transglutaminase à spécificité améliorée
US9044456B2 (en) 2008-06-18 2015-06-02 Lifebond Ltd. Cross-linked compositions
WO2009153751A3 (fr) * 2008-06-18 2011-01-20 Lifebond Ltd Procédé de réticulation enzymatique d'une protéine
WO2009153751A2 (fr) * 2008-06-18 2009-12-23 Lifebond Ltd Procédé de réticulation enzymatique d'une protéine
US10202585B2 (en) 2009-12-22 2019-02-12 Lifebond Ltd Modification of enzymatic crosslinkers for controlling properties of crosslinked matrices
US9822171B2 (en) 2010-04-15 2017-11-21 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US10047121B2 (en) 2010-08-14 2018-08-14 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins

Also Published As

Publication number Publication date
AU2003213718A1 (en) 2003-09-16
AU2003213718A8 (en) 2003-09-16
WO2003074004A3 (fr) 2006-08-10

Similar Documents

Publication Publication Date Title
US20030224476A1 (en) Method of producing transglutaminase reactive compound
WO2003074004A2 (fr) Procede de production d'antigenes
Bren et al. The N terminus of the flagellar switch protein, FliM, is the binding domain for the chemotactic response regulator, CheY
Oosawa et al. Overproduction of the bacterial flagellar switch proteins and their interactions with the MS ring complex in vitro
Sargent et al. Reassignment of the gene encoding the Escherichia coli hydrogenase 2 small subunit: identification of a soluble precursor of the small subunit in a hypB mutant
NZ223632A (en) Mycobacterium tuberculosis 540 and 517 amino acid proteins
US7101695B2 (en) Method of producing transglutaminase having broad substrate activity
JPWO2003056018A1 (ja) ピログルタミルペプチダーゼおよびその遺伝子
KR101528169B1 (ko) 아비박테리움 파라갈리나룸 항체의 검출방법 및 키트
US20030219853A1 (en) Method of cross-linking a compound
Hu et al. Morganella morganii urease: purification, characterization, and isolation of gene sequences
US6391574B1 (en) AFC1 and RCE1: isoprenylated CAAX processing enzymes
US7485438B2 (en) Method of producing polyvalent antigens
US5763284A (en) Methods for peptide synthesis and purification
US5834235A (en) Inferferon-α-induced protein
Chow et al. Characterization of Pen n 13, a major allergen from the mold Penicillium notatum
Andrin et al. Expression and purification of mammalian calreticulin in Pichia pastoris
US20040001848A1 (en) Method of producing disease-specific antigens
EP0234592A1 (fr) Plasmide contenant un fragment d'ADN codant pour la région Fc de protéine immunoglobuline G humaine, et son utilisation pour la production de ladite protéine
EP0286171B1 (fr) Dipeptidase, son isolation de bactéries produisant de l'acide lactique, anticorps contre cette dipeptidase, l'utilisation de cette dipeptidase et de l'anticorps
JPH07147979A (ja) 新規アミノペプチダーゼ
KR100425884B1 (ko) 살모넬라 타이피의 특정 항원성 외부막 단백질을 코딩하는 디엔에이 서열
JP4631436B2 (ja) メタロエンドペプチダーゼ
EP0497911B1 (fr) Production recombinee de lactoperoxydase
Blau Structure, genomic localization and recombinant expression of the mouse 6-pyruvoyl-tetrahydropterin synthase gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP